Michael W Konstan
Overview
Explore the profile of Michael W Konstan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
6898
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zemanick E, Ramsey B, Sands D, McKone E, Fajac I, Taylor-Cousar J, et al.
J Cyst Fibros
. 2025 Jan;
PMID: 39755444
Background: Highly effective CFTR modulators improve CFTR function and lead to dramatic improvements in health outcomes in many people with cystic fibrosis (pwCF). The relationship between measures of CFTR function,...
2.
Coughlin M, Sankararaman S, Roesch E, Certo E, Brej B, Konstan M
Front Pediatr
. 2024 Nov;
12:1457517.
PMID: 39507496
This case report presents a comprehensive evaluation of the complex balance of therapeutic benefits and potential risks associated with the cystic fibrosis transmembrane conductance regulator (CFTR) modulator elexacaftor/tezacaftor/ivacaftor (ETI) therapy...
3.
Joseph J, Perzynski A, Dungan K, Beverly E, Einstadter D, Fiegl J, et al.
Diabetes Care
. 2024 Oct;
48(1):38-46.
PMID: 39388337
Objective: To evaluate the Ohio Diabetes Quality Improvement Project (QIP) equity aim to reduce the percentage of Non-Hispanic Black (NHB) and Hispanic patients with A1C >9% by ≥20% over 2...
4.
Roesch E, Rahmaoui A, Lazarus R, Konstan M
Expert Rev Respir Med
. 2024 Aug;
18(9):677-691.
PMID: 39176450
Introduction: The availability of cystic fibrosis transmembrane conductance regulator (CFTR) modulators opens the possibility of discontinuing some chronic pulmonary therapies to decrease cystic fibrosis (CF) treatment burden. However, CFTR modulators...
5.
Konstan M, Polineni D, Chmiel J, Bilodeau L, Middleton P, Matouk E, et al.
J Cyst Fibros
. 2024 Jul;
24(1):83-90.
PMID: 38987119
Background: Lung inflammation is associated with tissue damage in cystic fibrosis (CF). LAU-7b, a novel oral drug candidate, was shown to control inflammation and stabilize CFTR protein in the epithelial...
6.
Samet J, El-Bassel N, Winhusen T, Jackson R, Oga E, Chandler R, et al.
N Engl J Med
. 2024 Jun;
391(11):989-1001.
PMID: 38884347
Background: Evidence-based practices for reducing opioid-related overdose deaths include overdose education and naloxone distribution, the use of medications for the treatment of opioid use disorder, and prescription opioid safety. Data...
7.
Beverly E, Koopman-Gonzalez S, Wright J, Dungan K, Pallerla H, Gubitosi-Klug R, et al.
JMIR Form Res
. 2024 Apr;
8:e55285.
PMID: 38607661
Background: The Ohio Cardiovascular and Diabetes Health Collaborative (Cardi-OH) unites general and subspecialty medical staff at the 7 medical schools in Ohio with community and public health partnerships to improve...
8.
Davis A, Knudsen H, Walker D, Chassler D, Lunze K, Westgate P, et al.
Lancet Reg Health Am
. 2024 Mar;
32:100710.
PMID: 38510790
Background: Community stigma against people with opioid use disorder (OUD) and intervention stigma (e.g., toward naloxone) exacerbate the opioid overdose crisis. We examined the effects of the Communities that HEAL...
9.
Stopka T, Babineau D, Gibson E, Knott C, Cheng D, Villani J, et al.
JAMA Netw Open
. 2024 Feb;
7(2):e240132.
PMID: 38386322
Importance: Buprenorphine significantly reduces opioid-related overdose mortality. From 2002 to 2022, the Drug Addiction Treatment Act of 2000 (DATA 2000) required qualified practitioners to receive a waiver from the Drug...
10.
Bolen S, Joseph J, Dungan K, Beverly E, Perzynski A, Einstadter D, et al.
Am J Public Health
. 2023 Oct;
113(12):1254-1257.
PMID: 37824811
We used a collective impact model to form a statewide diabetes quality improvement collaborative to improve diabetes outcomes and advance diabetes health equity. Between 2020 and 2022, in collaboration with...